TriLuma.com - For Professionals

8 Weeks: Mild Melasma -- Individual results may vary. In studies, 29% of patients achieved complete clearing. Tri-Luma® Cream is safe to use to complete clearing or when melasma recurs.

See what a leading dermatologist has to say about Melasma and its treatment

Is triple-action Tri-Luma® right for you?

Now, Tri-Luma® Cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) is indicated for short-term and intermittent long-term treatment of moderate to severe melasma¹

Proven safe for intermittent use up to six months within a 12-month period
No skin atrophy and no increase in severity of side effects versus short-term (8-week) use
Fluocinolone acetonide is a low-potency, class 6 steroid
The only melasma therapy that combines three active ingredients — a low potency corticosteroid (fluocinolone acetonide), hydroquinone, and tretinoin — in one stable formulation
Tri-Luma® Cream is for short-term and intermittent long-term therapy for up to six months of cumulative drug exposure.
Tri-Luma® Cream is the only hydroquinone (4.0%)-based product for Melasma approved by the FDA. A prominent healthcare professional speaks out about Tri-Luma® Cream – watch the video.

Fast, effective short-term and intermittent melasma therapy that's safe and well tolerated

A recent study showed quality of life improvement after using Tri-Luma® Cream¹,²
Clinically proven to lighten moderate-to-severe melasma in eight weeks.³
Visible lightening as early as 1 month with 77% of patients cleared or nearly cleared in 8 weeks.
Favorable safety profile and well tolerated by patients.³
Once-daily regimen, including a Sun Avoidance Program.
Only melasma therapy that combines three products in a single, elegant cream.

Reference:
1. Grimes P. Incidence and psychosocial implications of melasma. Presented at: American Academy of Dermatology; July 25-29, 2003; Chicago, Ill.
2. Grimes P, Kelly AP, Torok H, Willis I. PIGMENT: a community-based study of new treatment for melasma. Presented at: American Academy of Dermatology; July 25-29, 2003; Chicago, Ill.
3. Taylor SC, et al. Efficacy and Safety of a New Triple-Combination Agent for the Treatment of Facial Melasma. Cutis. 2003; 72: 67-72.

Please see full prescribing information.

Tri-Luma® Cream is contraindicated in individuals with a hypersensitivity, allergy or intolerance to fluocinolone acetonide, hydroquinone or tretinoin. In clinical trials, the most frequently reported side effects were erythema, desquamation, burning, dryness and pruritus.

Mild to moderate redness, peeling, burning, dryness or itching may be experienced. This product contains sulfites that may cause severe allergic reactions including anaphylactic symptoms and life-threatening asthma attacks. Exposure to sunlight, sunlamps or UV light and extreme heat, wind or cold should be avoided. Use of sunscreen with appropriate SPF of 30 or higher is required. Wear protective clothing and change to nonhormonal forms of birth control, if hormonal methods are used.

Tri-Luma® Cream contains hydroquinone, which may produce exogenous ochronosis, a gradual blue-black darkening of the skin, whose occurrence should prompt discontinuation of therapy. Tri-Luma® Cream contains the corticosteroid fluocinolone acetonide. Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for corticosteroid insufficiency after withdrawal of treatment.


	Prescribing Information © 2008 Galderma Laboratories, L.P. Legal and Privacy Statements This site is intended for U.S. audiences only. Contact Us En Español Unsubscribe